[ad_1]
Karo Healthcare has introduced their acquisition of the rights to the OTC model, Proctosedyl from Bayer. This enables the switch of possession to the OTC pharmaceutical Proctosedyl and unique license to their trademark in Italy, from Bayer to Karo.
It will broaden Karo’s presence inside Italy and continues their M&A ambitions of specializing in manufacturers with robust fairness.
Karo Healthcare have been offered authorized help by the workforce led by Stefano Giberti and Francesco Setti at Franzosi Dal Negro Setti which supported Karo all through this acquisition.
[ad_2]
